When Fame Meets the Shadow Pharmacy: Perry, Woods, and the Addiction Industry That Preys on Them

The "Ketamine Queen" gets 15 years for selling the drug that killed Matthew Perry. Tiger Woods faces a prescription drug investigation for crashing his car this month. Same week. Same broken system. What does accountability look like when addiction is a business model?

On Tuesday, April 8, a Los Angeles courtroom delivered what Matthew Perry's family had waited 30 months for. Jasveen Sangha, 42 - the North Hollywood woman federal prosecutors called "the Ketamine Queen" - was sentenced to 15 years in federal prison. She sobbed as Perry's relatives addressed the court. The judge told her she had shown no remorse in the years since her arrest. Sangha admitted, for the first time publicly, that her decisions had "shattered people's lives." She said she was "deeply ashamed and sorry."

Twenty-four hours later, a Florida court filing revealed that prosecutors are seeking all prescription drug records connected to Tiger Woods - a man who crashed his car in Martin County last month, was found with hydrocodone in his pocket, and told officers he had taken prescription medication earlier that morning. A breathalyser came back clean. A urinalysis was declined. The bodycam footage showed Woods - the most decorated golfer in history, a man who has rebuilt himself from career-ending back surgeries - kneeling on one knee on the side of a Florida road, calm, almost serene, telling officers: "I looked down at my phone, and all of a sudden, boom."

This is not a story about two famous people who got mixed up with drugs. That framing lets everyone else off the hook.

This is a story about an ecosystem - a shadow pharmaceutical network that targets the wealthy, the famous, and the deeply suffering. It is a story about doctors who abuse their prescribing authority for profit. About dealers who build clienteles from celebrity vulnerability. About a culture that treats addiction as a moral failing when the addict is poor and a medical condition when the addict is rich enough to afford ketamine therapy at $500 a session. And it is, ultimately, a story about what accountability looks like when the system finally catches up - and whether 15 years for one woman, and a drug records subpoena for one golfer, is justice or theater.

Perry's mother, Suzanne Perry, told the court: "Matthew, I love and miss you terribly. I am proud of who you were and how hard you fought." (Source: BBC News, April 8, 2026) Perry's stepfather, Keith Morrison, said in court that his death had left a "hole in our lives that will never be filled." Perry was 54 years old when he died, found in the hot tub of his Los Angeles home on October 28, 2023. He had spent 30 years fighting to survive. He had written a memoir about it. He had spoken openly about the terror of addiction in ways that made people feel less alone. And in his final months, he had found something that seemed like it might save him: ketamine therapy for depression.

What killed him was the same drug, administered illegally, in doses that should never have been approved, by people who saw not a patient but a revenue stream.

Who Jasveen Sangha Was - and How She Built Her Business

Federal authorities found dozens of ketamine vials during a raid on Sangha's Los Angeles home. Also found: thousands of pills including methamphetamine, cocaine, and Xanax. Prosecutors described the American-British dual national's operation as a "drug-selling emporium" - a curated, high-end supply network that served wealthy and well-connected clients from at least 2019.

This was not a street corner. Sangha did not sell to strangers. She sold to people who could afford premium product delivered with discretion, people with money and connections who needed someone they could trust. Federal records show she had been operating for years before Matthew Perry ever became a client - which means there were other customers, other deliveries, other transactions. Perry was not an anomaly in her business. He was a success story, until he wasn't.

Sangha was one of five people federal officials say supplied ketamine to Perry. The network stretched across Los Angeles. A San Diego-based physician - identified in court records as Salvador Plasencia - obtained ketamine from his clinic and a wholesale pharmaceutical distributor through a fraudulent prescription. Plasencia sold it to Eric Fleming. Fleming sold it to Perry. And Sangha sold to multiple people in the chain, functioning as a kind of high-volume wholesaler in a market that had no regulatory oversight and no accountability until bodies started appearing. (Source: BBC News)

Perry's live-in assistant, Kenneth Iwamasa, helped purchase and inject the actor with ketamine - a horrifying detail that speaks to how completely addiction can colonize a person's closest relationships, turning the people paid to care for someone into unwitting participants in their destruction. Iwamasa pleaded guilty. His sentencing has been requested to be postponed by his legal team and is expected later in 2026.

The doctors involved made the case more than a simple dealer story. Salvador Plasencia agreed to plead guilty after facing charges of obtaining ketamine through fraudulent means and distributing it illegally. That a licensed physician used institutional access - a clinic, a legitimate pharmaceutical distributor, the apparatus of legitimate medicine - to build a side business supplying illegal drug chains should provoke outrage far beyond the Perry family. It is a corruption of the entire framework of trust that allows medicine to function.

"You caused this. You who has talent for business enough to make money chose the one way that hurts people. Please give this heartless woman the maximum prison sentence so she won't be able to hurt other families like ours."- Debbie Perry, Matthew Perry's mother, in a victim impact statement submitted to the California court, April 2026 (Source: BBC News)

Sangha initially denied all charges. She changed her plea in August 2025, just weeks before trial was scheduled to begin - a maneuver her lawyers positioned as an act of responsibility. The judge did not agree. He noted she had shown no remorse during the years since her arrest and that she caused "irreversible" damage. He sentenced her to 15 years. Her lawyers had argued for leniency, citing no prior record and claiming she had "accepted responsibility for serious criminal conduct." The maximum possible sentence was 65 years.

What 15 years means in practice: Sangha will be eligible for release when she is around 57 years old. Matthew Perry will still be dead.

Perry's Own Words: What Addiction Actually Feels Like From the Inside

In November 2022, a year before his death, Matthew Perry published Friends, Lovers, and the Big Terrible Thing - a memoir that dispensed with the comfortable narrative of recovery arc. He did not write a redemption story. He wrote something harder: an honest account of a man who spent 30 years losing and winning a war against himself, who had been to rehab 15 times, who had spent nearly $9 million on sobriety treatments, who had faced near-death experiences that would have destroyed anyone else's will to live.

Perry wrote about being on a ventilator with a 2% chance of survival after his colon ruptured - a rupture caused by opioid overuse. He wrote about waking up in hospitals not knowing where he was. He wrote about the specific terror of not being able to imagine a future without substances. "Why is it me? Why am I like this?" he asked in the book. "There's no answer. All I can tell you is that I am an addict, and I am also one of the luckiest people alive."

He was in his early 50s when he began ketamine therapy for depression - a treatment that has gained significant clinical legitimacy in recent years. Ketamine is a dissociative anaesthetic with hallucinogenic properties that, administered in controlled clinical settings by licensed physicians, has shown genuine promise for treatment-resistant depression. The FDA approved Spravato - a nasal spray derivative - in 2019. Hundreds of legitimate ketamine clinics operate across the United States. For people like Perry, who had cycled through every other treatment option for decades, it was genuinely new hope.

The problem was that the line between legitimate ketamine therapy and what Sangha and the others were running had almost no visible boundary from Perry's perspective. He was getting ketamine in both cases. One was supervised, monitored, clinically appropriate. The other was a dealer using the language and aesthetics of therapy to charge premium prices for an illegal supply chain. Perry, whose addiction had rewired his entire relationship with risk assessment, could not necessarily tell the difference - or, by that stage, could not bring himself to care.

On the day he died, Perry's ketamine levels were found to be lethal. Investigators determined that the amount in his system was consistent with the doses used for general anaesthesia - levels at which any unmonitored person would lose consciousness with no one to intervene. He was alone in his hot tub. He was 54 years old. He had survived everything else.

Tiger Woods: The Second Fall, Same Pattern

Tiger Woods' March 2026 crash in Martin County, Florida, was his third DUI-adjacent incident in less than 20 years. In 2009, he drove into a fire hydrant at 2:30 in the morning outside his own home and was found to have sleeping pills in his system. In 2017, he was found asleep in a haphazardly parked car 15 miles from his home; a toxicology report found five drugs in his system, including oxycodone, Vicodin, Torix, Vioxx, and Ambien. He was not drunk in any of these incidents. He was, each time, dealing with the pharmaceutical aftermath of a body that had been through the extraordinary physical punishment of professional elite sport.

Woods has had at least five back surgeries. He has played through injuries that would have ended most careers a decade earlier. The pain is real - it has always been real - and the prescriptions that manage that pain exist at a clinical and ethical boundary that is genuinely hard to navigate. This is not a defense of driving impaired. It is context that the headlines rarely provide.

The April 2026 filing reveals that prosecutors are seeking all records connected to Woods' prescription medications, including dosages and specific warnings about "driving on pill bottles" - the warnings that pharmaceutical companies are legally required to print on medication packaging when a drug impairs motor function. Those warnings are there. The question prosecutors want answered is: did Woods take those medications knowing the warnings, and did his physicians adequately monitor his compliance? (Source: BBC News, April 9, 2026)

After his crash, Woods posted on X: "I know and understand the seriousness of the situation I find myself in today. I am stepping away for a period of time to seek treatment and focus on my health. This is necessary in order for me to prioritise my wellbeing and work toward lasting recovery."

That statement was praised as responsible and self-aware. Which it is. It is also exactly the kind of statement that wealthy, famous people with good PR teams are able to make - and which results in treatment, not arrest. Woods was charged with driving under the influence. He pleaded not guilty. He will not be in a cell tonight. He will be in a treatment program of his choosing, in a facility of his choosing, with lawyers of his choosing.

Jasveen Sangha will be in a federal prison for the next decade and a half. Cody McLaury, who bought ketamine from Sangha in August 2019 and died hours later, never got that choice. His name appears in Sangha's plea agreement - he is the second death attached to her supply chain, the one that did not make international headlines because he was not Chandler Bing.

The Race and Class Calculus of Drug Enforcement

The numbers on who goes to prison for drug offenses in the United States are not ambiguous. According to the Sentencing Project, Black Americans are imprisoned for drug offenses at more than twice the rate of white Americans, despite similar rates of drug use across racial groups. The Drug Policy Alliance documented in 2023 that more than 80% of people in federal prison for drug offenses are people of color. These are not ancient statistics. They describe the system that is operating right now, in the same courts where Jasveen Sangha was sentenced.

Sangha is a British-American woman of South Asian descent. Her clients were, by all accounts, predominantly white and wealthy. She received 15 years. That sentence will be parsed through multiple lenses depending on who is doing the parsing. Her lawyers argued it was excessive. Perry's family argued the maximum sentence was warranted. Criminologists who study drug sentencing note that 15 years for a first-time drug offender - absent prior criminal history - is substantially above the national average for comparable offenses, even accounting for the deaths attached to her supply chain.

For perspective: The physician who fraudulently prescribed and distributed ketamine, enabling the entire chain, and who had the institutional power and medical license to exploit - Salvador Plasencia has not yet been sentenced. His case is ongoing. The man with formal training, a clinic, a legitimate pharmaceutical distribution channel, and a legal obligation to protect patients used all of those institutional advantages to run a drug supply network. He had vastly more responsibility, in any clinical or ethical framework, than a dealer without medical training. Whether his sentence will reflect that responsibility remains to be seen.

"Ketamine is the most dangerous drug that nobody is talking about right now. The difference between a therapeutic dose and a lethal dose is narrower than most people realize, and there is virtually no supervision of the enormous shadow market that exists alongside the legitimate clinics."- Dr. Rahul Gupta, former director of the White House Office of National Drug Control Policy, in an interview with Politico (2024)

The opioid epidemic offers an instructive comparison. For years, Purdue Pharma - the family-controlled company behind OxyContin - aggressively marketed a drug they knew was highly addictive, downplaying addiction risks to physicians and patients alike. The result: more than 500,000 opioid overdose deaths in the United States between 1999 and 2019. The Sackler family, which owned Purdue, paid settlements worth billions of dollars. No member of the Sackler family was criminally convicted. No one went to prison. They paid their way out, negotiated legal immunity, and several remain among the wealthiest families in the world. Their name was removed from museum wings, but not from their bank accounts.

The supply chains that killed Matthew Perry and Cody McLaury are, in structure, a shadow reflection of the opioid epidemic: physicians who misuse their institutional access, distributors who move product without clinical supervision, and end-stage sellers who maintain the fiction of discretion and care while extracting maximum revenue from vulnerable clients. The difference is scale and visibility. The Sacklers operated through regulatory capture and political influence at the highest levels of government. Sangha operated out of a house in North Hollywood. The mechanism of exploitation was the same. The consequences were not.

The Booming Ketamine Industry and Its Dangerous Edge

This is the cultural context that makes the Perry case matter beyond celebrity gossip: ketamine is having a moment. A long, lucrative, mainstream moment.

After the FDA approved esketamine (Spravato) for treatment-resistant depression in 2019, a wave of ketamine infusion clinics opened across the United States. By 2023, there were more than 800 registered ketamine therapy providers in the country. Companies like Ketamine One and Mindbloom attracted venture capital. Silicon Valley investors began funding ketamine wellness startups. Celebrities and influencers began speaking publicly about ketamine's transformative effects on depression, trauma, and chronic pain - further normalizing what had previously been understood primarily as a club drug and a veterinary anaesthetic.

The legitimate market is real. Peer-reviewed research supports ketamine's efficacy for treatment-resistant depression and, in some protocols, for PTSD. The promise is genuine. But the market has expanded faster than oversight has followed. FDA regulations govern Spravato specifically but do not cover the vast majority of ketamine infusion practices, which operate under a "compounding" exemption and a patchwork of state medical board oversight that varies enormously in rigor. In practice, this means that the quality of supervision at ketamine clinics - the presence of monitoring equipment, the protocols for managing adverse reactions, the vetting of patient mental health histories - differs dramatically from clinic to clinic.

The Perry case exposed the darkest version of what happens when that regulatory gap is exploited. The drugs that killed him came from a physician who used a legitimate clinical infrastructure to divert pharmaceutical-grade ketamine into an illegal supply chain. The physician's patients presumably received supervised, appropriate care. The product he diverted went to a celebrity who was already known to have a severe addiction history, with no clinical supervision, no monitoring, no one to intervene when the dose was wrong.

The day after Sangha's sentencing, the same news cycle that covered Perry's case also noted that prosecuters are subpoenaing Tiger Woods' prescription records. Woods is dealing with an entirely different drug class - opioids and sedatives prescribed for genuine, documented, severe physical injury. But the structural similarity is striking: a famous person, a documented history of substance use across multiple incidents, a question about what his prescribing physicians knew and when, and a legal system that is now pursuing the prescription trail because the prescription trail is where the accountability lives.

Neither of these men created their vulnerabilities. Perry did not choose to become addicted; he experienced it as something that happened to him and spent three decades fighting it with every resource available. Woods did not choose to need back surgeries. What both of them encountered was a network of people who saw their vulnerability as an opportunity - for profit, for access, for proximity to fame.

What "Justice" Looks Like When Grief Enters the Courtroom

The courtroom on Tuesday was filled with people who loved Matthew Perry. His mother, Suzanne. His stepfather, Keith Morrison. His sister Maria. His half-siblings Caitlin, Emily, and Will. They read impact statements into the record - descriptions of grief that will outlast any sentence, any plea deal, any legal proceeding the US justice system can generate.

Debbie Perry, Matthew's biological mother, was direct: "Please give this heartless woman the maximum prison sentence so she won't be able to hurt other families like ours."

The maximum was 65 years. The sentence was 15. Whether that gap represents judicial wisdom or institutional inadequacy depends on your framework. Criminal defense advocates would argue that lengthy prison sentences for drug distribution - even in cases involving death - do not deter drug markets, do not reduce addiction, and do not make communities safer. They would point to the 50-year war on drugs, which has produced the largest prison population in human history without meaningfully reducing drug use or availability.

They would not be wrong. And it would feel entirely inadequate to say this to Debbie Perry.

This is the unbridgeable gap at the center of drug policy: the families who lose someone need an accounting that the justice system is structurally incapable of providing. Prison gives them a body in a cell. It does not give them their person back. It does not dismantle the market that killed their person. It does not guarantee that another person in another hot tub in another expensive Los Angeles home won't die next month from the same chain of choices and greed and pharmaceutical exploitation.

The justice system processed five people in the Perry case. All five have pleaded or will plead guilty. All five will be sentenced. And when the last sentencing is done - when Kenneth Iwamasa gets his date and Eric Fleming gets his - the ketamine shadow market will still be operating. Other wealthy, vulnerable people will still be accessing it. Other dealers will have replaced Sangha. The system has achieved accountability for one case. It has not addressed the conditions that make the case possible.

The Human Calculus: What Perry Wanted People to Know

In the last chapter of his memoir, Perry wrote that he wanted his legacy to be his sobriety - not Friends, not Chandler Bing, not the fame. He wanted to be the person who told the truth about addiction in a culture that still, despite decades of ostensible progress, prefers to treat it as a character flaw.

He had plans, at the time of his death, to convert his Malibu home into a sober living facility for men. He had already been running a virtual support system called the Perry House, providing free resources for people in recovery. He mentored people he did not know. He answered messages from strangers who were struggling. He believed, as someone who had nearly died multiple times, that the most important thing he could do with the improbable fact of his survival was to make other people feel less alone in theirs.

The Perry Foundation, established after his death, continues that work. His family has been directing attention there as the legal proceedings concluded - a reminder that grief, when it finds somewhere to go, can become something constructive without becoming comfortable.

Tiger Woods, for his part, issued a statement about seeking treatment and working toward "lasting recovery" - language that mirrors what Perry said publicly countless times throughout his career. Whether Woods finds that recovery, whether the legal system creates enough accountability to prompt genuine change, whether the prescription trail leads to physicians who will lose their licenses or merely pay fines - none of that is settled yet.

What is settled is this: two of the most famous athletes and entertainers of their generations ended up, in the same week, caught in the same grinding machinery of American addiction culture. A culture that profits from vulnerability, that markets pharmacological escape as wellness, that allows a network of physicians and dealers and assistants to circle the most desperate and the most famous and extract from them until there is nothing left to extract.

The Ketamine Queen will serve her 15 years. The families will carry what they carry. The market will continue, because markets do not wait for sentencing hearings. The lesson, if there is one, is that accountability for individuals - even when it arrives - is not the same as accountability for systems. And the system that killed Matthew Perry and is now investigating Tiger Woods is not a broken system. It is working exactly as designed.

That is what needs to change.

The Timeline: From Perry's Diagnosis to Sangha's Sentence

Sources: BBC News (Sangha sentencing, April 2026) | BBC News (Tiger Woods prescription probe, April 2026) | Friends, Lovers, and the Big Terrible Thing by Matthew Perry (Flatiron Books, 2022) | US Department of Justice case filings | Sentencing Project research on drug offense disparities | FDA guidance on ketamine therapy and Spravato | Drug Policy Alliance data on incarceration rates